Empowering surgeons. Rewarding innovation. Regenerating lives.

We are LOCATE BIO and we are building a world leading, diversified orthobiologics company that is focused on providing surgeons with a choice of best-in-class products.

Read more

Relieving suffering and restoring quality of life with breakthrough products.

LDGraft™ *

Feed the Fusion

LDGraft is an exciting rhBMP-2 product in development, currently in a clinical trial for lumbar interbody fusion procedures.

LDGraft also has an FDA Breakthrough Device designation for the Anterior Lumbar Interbody Fusion (ALIF) indication at one level from L3-S1 for patients with degenerative disc disease.

Read more
* For investigational use only, not approved for sale

Who we are

LOCATE BIO is an innovative UK MedTech company with industry-leading drug delivery and tissue scaffold capabilities.

Purpose

Developing next-generation solutions that address unmet musculoskeletal needs

Culture

Unleashing and realising potential within a fearless organisation

Strategy

Develop next-generation products capable of dominating each of their market segments

Read more

Meet the Team

A dedicated team of industry-leading experts.

John von Benecke

Chief Executive Officer

Hyun W. Bae, MD

Chief Medical Officer

Keith Valentine

Non-Executive Chair

Tyler Lipschultz

President of Locate Bio Inc

Colin Thomson

Chief Financial Officer

Robyn Cochrane

QARA and Clinical Director

Lyndsey Johnson

Scientific Programme Manager

Victoria Oldham

HR Manager

Charles Matthews

Lead Scientist

Ian Wilding

Non-Executive Director

Alex Gwyther

Non-Executive Director

Jon Earl

Non-Executive Director

View all